Ignite Creation Date:
2025-12-24 @ 12:31 PM
Ignite Modification Date:
2026-01-26 @ 10:56 AM
Study NCT ID:
NCT02180061
Status:
COMPLETED
Last Update Posted:
2020-03-31
First Post:
2014-07-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-07-15
Start Date Type:
ACTUAL
Primary Completion Date:
2017-08-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-08-31
Completion Date Type:
ACTUAL
First Submit Date:
2014-07-01
First Submit QC Date:
None
Study First Post Date:
2014-07-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-08-10
Results First Submit QC Date:
None
Results First Post Date:
2016-10-04
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-03-20
Last Update Post Date:
2020-03-31
Last Update Post Date Type:
ACTUAL